MUSE impotence drug beats Viagra to market
Article Abstract:
Janssen-Ortho Inc. has introduced in Canada the much awaited male impotence treatment MUSE, almost two months before doctors can start prescribing Viagra. The company is marketing the treatment in the US under a deal with Menlo Park, CA-based Vivus Inc., which developed the treatment. MUSE, which is an acronym for medicated urethral system for erection, is a disposable applicator with a micropellet of the drug alprostadil. The applicator is inserted at the end of the urethra and the drug is locally absorbed. The treatment works by increasing blood flow to the penis by opening blood vessels.
Comment:
Launches in Canada the much awaited male impotence treatment MUSE, almost two months before doctors can start prescribing Viagra
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
The brains behind SignalGene
Article Abstract:
The article profiles Montreal's SignalGene Inc., a biotech firm focused on searching for the 10 to 12 genetic triggers for Alzheimer's disease. The company, which was just restructured, has raised $22-million in new equity, purchased companies GeneScape Inc. and Nanodesign Inc., and expanded its overall genetic research to include psoriasis, obesity, breast cancer, and osteoporosis.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Air Canada pilots poised to strike. Judge reins in Air Canada
- Abstracts: Pancon drifts into view. The big drill
- Abstracts: Gener therapy for heart patient a first. Want health care in Canada? Sign this waiver
- Abstracts: Microsoft deal worries Apple. Why the Web's not ready for prime time
- Abstracts: TSE to probe trading in Inco's VBN shares. Senator leery of new financial regulations